Osteoarthritis (OA) is a degenerative joint disease. CASA1, encoded by CSN1S1, was identified to trigger the secretion of pro-inflammatory cytokines. However, its specific pathogenic role and the underlying molecular mechanisms in OA progression remain elusive. We analyzed the expression of CASA1 in human OA infrapatellar fat pad and synovium using single-cell RNA sequencing, and immunohistochemistry. The functional effects of CASA1 were evaluated in primary chondrocytes and in mouse models. Pain sensitivity and gait alterations were assessed using Von Frey and TreadScan tests. Cartilage degeneration was evaluated by MicroCT, histology, and OARSI scoring. Mechanistic explorations were conducted via RNA-seq, western blotting, transmission electron microscopy (TEM), and untargeted metabolomics. Rescue experiments were performed using Caffeic Acid Phenethyl Ester (CAPE) to validate the pathways involved. CASA1 was significantly overexpressed in OA infrapatellar fat pad and synovium. Functionally, CASA1 suppressed anabolism while promoting catabolism in chondrocytes. In vivo, intra-articular injection of CASA1 induced pain hypersensitivity, gait disorders, osteophyte formation, and severe cartilage erosion, accompanied by elevated inflammatory. Mechanistically, CASA1 activated the NF-κB and MAPK pathways. Furthermore, CASA1 triggered mitochondrial dysfunction via glutathione depletion, as confirmed by TEM and metabolomic profiling. Notably, pharmacological inhibition of NF-κB/MAPK by CAPE effectively reversed CASA1-induced chondrocyte degeneration in vitro and significantly alleviated pain, gait abnormalities, and cartilage damage in vivo. Our findings demonstrated that CASA1 serves as a novel factor driving OA pathogenesis through the activation of NF-κB/MAPK cascades and GSH-depletion-mediated mitochondrial injury. Targeting CASA1 downstream pathways, particularly with CAPE, may represent a promising therapeutic approach for OA treatment.